Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | OGFRL1 | Q5TC84 | 14/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17232256 | 0.98 | KDM4E (0.46) | KDM4EMEN1KMT2AOGFRL1OPRM1 | |
| SCHEMBL17232254 | 0.91 | OGFRL1 (0.46) | KDM4EMEN1KMT2AOGFRL1OPRM1 | |
| SCHEMBL17232248 | 0.90 | OPRL1 (0.46) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL15856598 | 0.90 | OGFRL1 (0.53) | KDM4EMEN1KMT2AOGFRL1OPRM1 | |
| SCHEMBL17222491 | 0.90 | OGFRL1 (0.53) | KDM4EMEN1KMT2AOGFRL1OPRM1 | |
| SCHEMBL17222490 | 0.90 | OGFRL1 (0.53) | KDM4EMEN1KMT2AOGFRL1OPRM1 | |
| SCHEMBL17232255 | 0.88 | OGFRL1 (0.45) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL17222482 | 0.88 | KDM4E (0.43) | KDM4EMEN1KMT2AOGFRL1OPRM1 | |
| SCHEMBL17222481 | 0.88 | KDM4E (0.43) | KDM4EMEN1KMT2AOGFRL1OPRM1 | |
| SCHEMBL15856604 | 0.88 | KDM4E (0.43) | KDM4EMEN1KMT2AOGFRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963458-B2 | Indole and indoline-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20150315201-A1 | INDOLE AND INDOLINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315201-A1 | INDOLE AND INDOLINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | IDO1, IDO2, TPH2 | KDM4E 1140/4885MEN1 4486/4885KMT2A 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.